Overview
This study mainly evaluated the safety and tolerability of HRS-1893 in subjects with non-obstructive hypertrophic cardiomyopathy, and the efficacy and plasma concentrations of different dosing regimens in subjects with non-obstructive hypertrophic cardiomyopathy.
Eligibility
Inclusion Criteria:
- Age 18~85 years old (including boundary value), male or female.
- Body mass index < 35 kg/m2.
- Understand the study procedures and methods, voluntarily participate in this trial, and sign the informed consent form in writing.
- Female subjects of childbearing potential must have a serum pregnancy test prior to the first dose with a negative result and must be non-lactating during the study.
- Female subjects of childbearing potential and male subjects whose partners are women of childbearing potential must agree to refrain from donating sperm/eggs from the time of signing the informed consent form until 3 months after the last dose of the trial drug, and comply with the relevant contraceptive requirements.
Exclusion Criteria:
- Known or suspected infiltration, hereditary, or storage disorder that can cause myocardial hypertrophy.
- Paroxysmal atrial flutter or atrial fibrillation with clinical symptoms at screening.
- History of syncope or sustained ventricular tachycardia within 6 months prior to screening.
- Those who have participated in the clinical trial of any drug or medical device within 3 months before screening.
- Other conditions that the investigator considers the subject to be unsuitable for participating in this trial.